Наша группа организует более 3000 глобальных конференций Ежегодные мероприятия в США, Европе и США. Азия при поддержке еще 1000 научных обществ и публикует более 700 Открытого доступа Журналы, в которых представлены более 50 000 выдающихся деятелей, авторитетных учёных, входящих в редколлегии.
Журналы открытого доступа набирают больше читателей и цитируемости
700 журналов и 15 000 000 читателей Каждый журнал получает более 25 000 читателей
Neelutpal Gogoi
Development of resistance by the malaria parasite Plasmodium falciparum has put challenges in the eradication of deadly malaria disease. Hence, newer strategies are being considered to combat this disease and research programmes with the target of new lead identification are going on worldwide to develop new chemotherapeutic agents. In this study, flavonoids found mainly in the fruits of Citrus species having traditional use in malaria-associated fever were selected for in silico multiple-target directed screening against three vital targets of the parasite namely, dihydrooroate dehydrogenase (PfDHODH), dihydrofolate reductase thymidine synthase (PfDHFR-TS) and plasma membrane P-type cation translocating ATPase (PfATP4) to find out new lead molecule(s). The in silico screening was carried out using different protocols of the Biovia Discovery Studio 2018 software and Network analyzer plugin of Cytoscape 3.6.0 followed by in vitro screening of the best lead. The selected lead was found to have good binding affinity against PfDHODH and PfATP4 with –CDocker energy 42.2719 and 33.1447 with respect to their co-crystal ligands. These findings were also supported by Structure-based Pharmacophore, DFT (Density Functional Theory) study and also by in vitro evaluation of the lead which showed IC50 value of 8.23 µm and 12.41 µm against 3D7 (chloroquine-sensitive) and RKL-9 (chloroquine-resistant) strain of P. falciparum respectively. This study could identify a moderately active lead molecule with prediction of mode of action. The research outcome can be utilized to design new antimamarial compounds by targeting the two enzymes.